title: Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in mantle cell lymphoma?
abstract: 2-[Fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) scanning is used for response assessment in mantle cell lymphoma (MCL). However, its ability to predict outcome is debatable. We retrospectively evaluated the prognostic impact of interim and post therapy FDG-PET/CT scan on outcome of 58 consecutive MCL patients. Scans performed at diagnosis, mid-therapy, post-chemotherapy and post-transplant were reviewed and outcome analyzed. Median age was 59; MCL International Prognostic Index (MIPI) was low in 45%, intermediate in 41% and high in 14%. Thirty-four patients (58%) received R-CHOP (rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone) or R-CHOP-like chemotherapy, 24 (42%) underwent upfront autologous stem-cell transplant (ASCT). Three-year overall (OS) and progression-free-survival (PFS) were 81% and 45%, respectively. No differences in OS or PFS between PET-positive and PET-negative groups both for interim and post-therapy scans were observed. We conclude that in patients treated with R-CHOP, using the International-Harmonization-Project criteria for FDG-PET/CT interpretation, there is no role for interim or post-therapy PET.
authors.affiliation: Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center , Tel-Hashomer , Israel.
authors.forename: Meirav
authors.initials: M
authors.lastname: Kedmi
authors.forename: Irit
authors.initials: I
authors.lastname: Avivi
authors.forename: Elena
authors.initials: E
authors.lastname: Ribakovsky
authors.forename: Noam
authors.initials: N
authors.lastname: Benyamini
authors.forename: Tima
authors.initials: T
authors.lastname: Davidson
authors.forename: Elinor
authors.initials: E
authors.lastname: Goshen
authors.forename: Tamar
authors.initials: T
authors.lastname: Tadmor
authors.forename: Arnon
authors.initials: A
authors.lastname: Nagler
authors.forename: Abraham
authors.initials: A
authors.lastname: Avigdor
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D017063:Outcome Assessment, Health Care / Q000379:methods* / Q000706:statistics & numerical data; D049268:Positron-Emission Tomography / Q000379:methods*; D011241:Prednisone / Q000008:administration & dosage; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D000069283:Rituximab; D033581:Stem Cell Transplantation / Q000379:methods; D014057:Tomography, X-Ray Computed / Q000379:methods*; D014182:Transplantation, Autologous; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D019788:Fluorodeoxyglucose F18; D000069283:Rituximab; D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone; D003630:Daunorubicin
keywords: FDG-PET/CT; Mantle cell lymphoma; overall survival; progression-free survival